Viet Reader.

Loading...

Viet Reader.

VR.

Premier Newspaper for Vietnamese Worldwide

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

American Society of Clinical Oncology confers highest honor upon Prof Hagop Kantarjian

SUZHOU, China and ROCKVILLE, Md., June 5, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Clinical Advisory Board member Prof Hagop M. Kantarjian has received the David A. Karnofsky Memorial Award for his lifelong contributions to leukemia clinical research and his dedication to improving the lives of patients.


Prof Kantarjian received the award at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023, in Chicago, IL. The David A. Karnofsky Memorial Award is considered the highest honor that ASCO confers and has been presented annually since 1970 to recognize an oncologist who has made outstanding contributions to cancer research, diagnosis, and/or treatment.

Prof Kantarjian is The Chairman of the Department of Leukemia and Samsung Distinguished University Chair in Cancer Medicine at The University of Texas MD Anderson Cancer Center. For the past four decades, Prof Kantarjian has led practice-changing national and international clinical trials at MD Anderson for the treatment of all leukemia subtypes. These trials resulted in multiple Food and Drug Administration (FDA)-approved drugs and delivered new standards of care across leukemias, significantly improving quality of life and survival rates across several leukemia subsets. Over the last two decades, Prof Kantarjian has led national and international studies of innovative next-generation BCR-ABL1 tyrosine kinase inhibitors.

"Throughout a remarkable career, Dr. Kantarjian has contributed immensely to our mission of ending cancer. He not only advanced new treatments and furthered our knowledge of leukemia, but his leadership has inspired so many in the MD Anderson community," said Prof Peter WT Pisters, President of MD Anderson. "We congratulate Hagop on this exceptional achievement, and we thank him for the countless lives he has saved around the world."

Prof Kantarjian's ground-breaking work has culminated in the publication of more than 2,200 peer-reviewed papers and 100 book chapters. In 2012, Prof Kantarjian co-founded the world-renowned Society of Hematologic Oncology (SOHO) to foster research, education, prevention, clinical trials, and the optimization of care for patients with hematologic malignancies and related disorders. Since its founding and under Prof Kantarjian's leadership, SOHO has expanded to include nearly 7,000 members from 110 countries. A nonresident fellow in health care at the Rice Baker Institute (Houston, TX), Prof Kantarjian has written extensively on critical issues in contemporary cancer medicine, including universal equitable health care and the value of the Affordable Care Act, among other vital topics.

"Dr. Kantarjian has dedicated his life to saving and enhancing the lives of patients with leukemia, renewing hope to millions of patients with unmet medical needs," said Dajun Yang, MD, PhD, Chairman of Ascentage Pharma "For decades, he has been at the forefront of the oncology community's efforts to end cancer. We are privileged that Dr. Kantarjian has chosen to share his wise counsel with our organization while serving with honor and distinction on the Ascentage Pharma Clinical Advisory Board."

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a globally focused biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. On October 28, 2019, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company has built a pipeline of 9 clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, Europe, and China. Ascentage Pharma has been designated for multiple Major National R&D Projects, including five Major New Drug Projects, one New Drug Incubator status, four Innovative Drug Programs, and one Major Project for the Prevention and Treatment of Infectious Diseases.

Olverembatinib, the company's core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company's first approved product, has been granted two Priority Review Designations and two Breakthrough Therapy Designations (BTDs) by the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA). To date, the drug had been included into the China 2022 National Reimbursement Drug List (NRDL). Furthermore, olverembatinib has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US FDA, and an Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has obtained a total of 16 ODDs from the US FDA and 1 Orphan Designation from the EMA of the EU for 4 of the company's investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic, Dana-Farber Cancer Institute, MSD, and AstraZeneca. The company has built a talented team with global experience in the discovery and development of innovative drugs and is setting up its world-class commercial manufacturing and Sales & Marketing teams. One pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs, in order to fulfil its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, Ascentage Pharma undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.


Source: Ascentage Pharma Related Stocks: HongKong:6855

About author
You should write because you love the shape of stories and sentences and the creation of different words on a page.
View all posts